Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)
Bioanalytical methods are applied at the development and test of drugs as well as at the step of pharmaceutic products issue. Drugs and excipients quality estimation is made by means of precise and reproducible methods. Accuracy and reproducibility of a method is established during validation which...
Saved in:
Published in | Farmaciâ i Farmakologiâ (Pâtigorsk) Vol. 4; no. 6; pp. 54 - 71 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English Russian |
Published |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
01.03.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Bioanalytical methods are applied at the development and test of drugs as well as at the step of pharmaceutic products issue. Drugs and excipients quality estimation is made by means of precise and reproducible methods. Accuracy and reproducibility of a method is established during validation which is obligatory for medicine registration. The principal task of method validation is experimental evidence of its suitability for the objectives to be achieved. Validation of bioanalytical methods is one of the elements of the whole medicine production validation [1, 2].The aim of research: to validate a method for determination of specific anti-hemolytic activity of eculizumab developed in LCC “IBC Generium”.Materials and methods: eculizumab, antibody-sensitized chicken erythrocytes, complement-containing human serum.Results. We demonstrated the specificity of the method and its correspondence to criteria of accuracy (103.0±1.4)%, robustness (CV – 11.5%), repeatability (CV – (4.9±0.9)%), reproducibility (CV – (3.5±0.4)%), and linearity (k -1.0275; R2 – 0.9975) during validation. The system validity (equipment, materials, analytical operations and analyzed samples) was confirmed for true results obtaining during validation.Results discussion. Experimental evidence of suitability of the method for eculizumab specific activity assessment was obtained in course of validation. The simplicity of the method allows obtaining accurate results in other laboratories. The developed method can be used not only for specific activity of Soliris determination but also for other pharmaceutical substances and drugs based on antibodies specific to human complement C5. |
---|---|
AbstractList | Bioanalytical methods are applied at the development and test of drugs as well as at the step of pharmaceutic products issue. Drugs and excipients quality estimation is made by means of precise and reproducible methods. Accuracy and reproducibility of a method is established during validation which is obligatory for medicine registration. The principal task of method validation is experimental evidence of its suitability for the objectives to be achieved. Validation of bioanalytical methods is one of the elements of the whole medicine production validation [1, 2].The aim of research: to validate a method for determination of specific anti-hemolytic activity of eculizumab developed in LCC “IBC Generium”.Materials and methods: eculizumab, antibody-sensitized chicken erythrocytes, complement-containing human serum.Results. We demonstrated the specificity of the method and its correspondence to criteria of accuracy (103.0±1.4)%, robustness (CV – 11.5%), repeatability (CV – (4.9±0.9)%), reproducibility (CV – (3.5±0.4)%), and linearity (k -1.0275; R2 – 0.9975) during validation. The system validity (equipment, materials, analytical operations and analyzed samples) was confirmed for true results obtaining during validation.Results discussion. Experimental evidence of suitability of the method for eculizumab specific activity assessment was obtained in course of validation. The simplicity of the method allows obtaining accurate results in other laboratories. The developed method can be used not only for specific activity of Soliris determination but also for other pharmaceutical substances and drugs based on antibodies specific to human complement C5. |
Author | Sazonova, E. V. Vishnevskiy, A. Yu Poroshin, G. N. Lyagoskin, I. V. Abbasova, S. G. Prudnikova, E. Yu Kudina, N. K. |
Author_xml | – sequence: 1 givenname: E. Yu orcidid: 0000-0002-7983-5312 surname: Prudnikova fullname: Prudnikova, E. Yu – sequence: 2 givenname: G. N. surname: Poroshin fullname: Poroshin, G. N. – sequence: 3 givenname: N. K. surname: Kudina fullname: Kudina, N. K. – sequence: 4 givenname: I. V. surname: Lyagoskin fullname: Lyagoskin, I. V. – sequence: 5 givenname: E. V. surname: Sazonova fullname: Sazonova, E. V. – sequence: 6 givenname: A. Yu surname: Vishnevskiy fullname: Vishnevskiy, A. Yu – sequence: 7 givenname: S. G. surname: Abbasova fullname: Abbasova, S. G. |
BookMark | eNo9kEtPwzAQhC1UJErpfwg3OBj8tnNEFY9KRRyAs-U4G2qUxJXjViq_npQCl93VzOjTas7RpI89IHRJyQ0tqeK3jBONS6YUZoQqLLDCUmBNT9CUCcoxG-dkvP9iZ2g-DKEiQimmiVJTBM-Q17EuathBGzcd9LlwfV3sXBtql0Psiyam0c6QutAfldiMmRzW0MV2n4MvnM9hF_L-4IDftuFr27mquHqNbUhhuL5Ap41rB5j_7hl6f7h_Wzzh1cvjcnG3wp4xTrGThsnSi5pqD4wLR4xQ1FDBQWitvZENlA1XjNQVMcRUDipe1s5wLTkYz2doeeTW0X3aTQqdS3sbXbA_Qkwf1qXx4RYsZcYzcIRw1QgFIxcqQksptJRUKDmyyiPLpzgMCZp_HiX2p3576NUeerWH-q2wykphNeXfLq96zg |
CitedBy_id | crossref_primary_10_21519_0234_2758_2020_36_1_73_86 crossref_primary_10_1002_cbdv_202201258 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.19163/2307-9266-2016-4-6-54-71 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2413-2241 |
EndPage | 71 |
ExternalDocumentID | oai_doaj_org_article_128c2ea0036f46ee9feb019547551465 10_19163_2307_9266_2016_4_6_54_71 |
GroupedDBID | AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ |
ID | FETCH-LOGICAL-c2231-a58259c4d17ce234a084618143e4777c85fe9f3620db0808baeb39da83753e8c3 |
IEDL.DBID | DOA |
ISSN | 2307-9266 |
IngestDate | Thu Jul 04 21:05:11 EDT 2024 Thu Sep 26 19:49:31 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2231-a58259c4d17ce234a084618143e4777c85fe9f3620db0808baeb39da83753e8c3 |
ORCID | 0000-0002-7983-5312 |
OpenAccessLink | https://doaj.org/article/128c2ea0036f46ee9feb019547551465 |
PageCount | 18 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_128c2ea0036f46ee9feb019547551465 crossref_primary_10_19163_2307_9266_2016_4_6_54_71 |
PublicationCentury | 2000 |
PublicationDate | 2017-03-01 |
PublicationDateYYYYMMDD | 2017-03-01 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Farmaciâ i Farmakologiâ (Pâtigorsk) |
PublicationYear | 2017 |
Publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
Publisher_xml | – name: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
SSID | ssib046627066 ssib027512512 ssib044736779 ssib015895657 ssib051327300 ssj0001921167 |
Score | 2.0365376 |
Snippet | Bioanalytical methods are applied at the development and test of drugs as well as at the step of pharmaceutic products issue. Drugs and excipients quality... |
SourceID | doaj crossref |
SourceType | Open Website Aggregation Database |
StartPage | 54 |
SubjectTerms | антигемолитическая активность валидация воспроизводимость линейность правильность прецизионность специфичность экулизумаб |
Title | Method development and validation for determination of antihemolytic activity of eculizumab (Soliris) |
URI | https://doaj.org/article/128c2ea0036f46ee9feb019547551465 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NaxsxEBUlh9BLSNKWfKNCMS1YxNLqa49JaDAtLQmxwTchabXEkNghsQ_Or8-M1s1uTrn0sgftrmBHg-bNzug9Qr7xUGnJhWdlgmVAQm8WbF2xoLUtfPQmpsz2-VcPx_LXRE06Ul_YE9bQAzeGO4X9M4rkkTelljqlsk4BD7lJg7FeN-ylXHWSKfAkrmzZrecJo94EcilNoU1bn5JIg97hNVeQoyGRe_u3phRYsMhKdQPDSghrm-RrPuwHgOb0dRCcjmsmmWYK2xzfBLuOJkAOXpfbZGuNOulZ87U75MPjcpf0rhra6lWfjtpTWE992qNXLaH16hNJf7LMNK3aBiPqZxUFJ502kkwUoC_cXnfW5JF5Dc8sprfpfn63gnkpnqBAoQq8g4q80-flvQ_0-838bgo7zY_PZHz5c3QxZGt5BhYBU3DmFWSXZZQVhwUVhfQDwDIAGGSRpDEmWuxjqyFADqoAuNQGD4l7WXlIiVWRbCy-kI3ZfJb2CFU-6prHCquU0oralwGWxArY_CK4Tr1PxD87uoeGhcNh9oLGd2h8h8Z3aHwnnXZKOsP3yTla_PUFJNLOA-Bebu1e7j33OvgfkxySjwLRQG5dOyIbi8dlOgYsswgn2W3h-vvavgBo4OS6 |
link.rule.ids | 315,786,790,870,2115,27957,27958 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Method+development+and+validation+for+determination+of+antihemolytic+activity+of+eculizumab+%28Soliris%29&rft.jtitle=Farmaci%C3%A2+i+Farmakologi%C3%A2+%28P%C3%A2tigorsk%29&rft.au=E.+Yu.+Prudnikova&rft.au=G.+N.+Poroshin&rft.au=N.+K.+Kudina&rft.au=I.+V.+Lyagoskin&rft.date=2017-03-01&rft.pub=Volgograd+State+Medical+University%2C+Pyatigorsk+Medical+and+Pharmaceutical+Institute&rft.issn=2307-9266&rft.eissn=2413-2241&rft.volume=4&rft.issue=6&rft.spage=54&rft.epage=71&rft_id=info:doi/10.19163%2F2307-9266-2016-4-6-54-71&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_128c2ea0036f46ee9feb019547551465 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2307-9266&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2307-9266&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2307-9266&client=summon |